Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies

Prostate Cancer and Prostatic Diseases volume 15, pages 182–188 (2012)Cite this article

Abstract

BACKGROUND: Various interferences can cause spurious results for common laboratory tests. Although rare, heterophilic antibodies may produce false elevations in PSA that could prompt unnecessary therapy in men previously treated for prostate cancer. The aim of this study was to determine the prevalence of small, spurious PSA elevations, and the role of heterophilic antibodies.

METHODS: Phase I: all PSA tests drawn and measured between 27 October 2008 and 26 October 2010 at Vanderbilt University Medical Center were analyzed (n=17 133). Patients who had been treated for prostate cancer with PSA values that changed from undetectable to detectable were evaluated. Phase II: patients with a detectable PSA ⩽0.5 ng ml−1 measured between 24 October 2010 and 19 January 2011 were studied prospectively (n=1288). If any patient had a previously undetectable PSA value, their serum was tested for heterophilic antibody interference.

RESULTS: Phase I: 11 men had a spuriously elevated PSA after curative treatment for prostate cancer (0.3%). Mean time to PSA elevation was 3.4±5.5 years, and mean elevation in PSA was 0.33±0.28 ng ml−1. Each patient's PSA was undetectable after being repeated, and no patient went on to unnecessary treatment. Phase II: 10 men had a newly detectable PSA, 9 of whom had a history of prostate cancer. Each tested negative for interfering heterophilic antibodies when their PSA test was repeated with a heterophilic antibody-blocking reagent.

CONCLUSIONS: In a large cohort, we estimate the prevalence of spuriously elevated PSA values in our population to be 0.3%. No patient with a prostate cancer history was subjected to unnecessary diagnostic evaluation or treatment. On prospective evaluation of PSA conversion to low detectable levels, no patient had evidence of interfering heterophilic antibodies. When using PSA for post-treatment surveillance, it is crucial to confirm all concerning values and consider the presence of a spurious elevation in PSA if the value does not correlate with the clinical scenario.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Loeb S, Schaeffer EM, Chan DW, Carter HB, Walsh PC, Sokoll LJ . Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation. Urology 2009; 73: 947–949.

    Article  Google Scholar 

  2. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 2008; 54: E11–E79.

    Article  CAS  Google Scholar 

  3. Henry N, Sebe P, Cussenot O . Inappropriate treatment of prostate cancer caused by heterophilic antibody interference. Nat Clin Pract Urol 2009; 6: 164–167.

    PubMed  Google Scholar 

  4. Fritz BE, Hauke RJ, Stickle DF . New onset of heterophilic antibody interference in prostate-specific antigen measurement occurring during the period of post-prostatectomy prostate-specific antigen monitoring. Ann Clin Biochem 2009; 46 (Pt 3): 253–256.

    Article  CAS  Google Scholar 

  5. Park S, Wians Jr FH, Cadeddu JA . Spurious prostate-specific antigen (PSA) recurrence after radical prostatectomy: interference by human antimouse heterophile antibodies. Int J Urol 2007; 14: 251–253.

    Article  CAS  Google Scholar 

  6. Morgan BR, Tarter TH . Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer. J Urol 2001; 166: 2311–2312.

    Article  CAS  Google Scholar 

  7. Camacho T, Mora J, Segura A, Guitian J, Lema F, Bandin J et al. Falsely increased prostate-specific antigen concentration attributed to heterophilic antibodies. Ann Clin Biochem 2002; 39 (Pt 2): 160–161.

    Article  Google Scholar 

  8. McAuley I, Steinhoff G, McNeely M, Blood P . Incorrect biochemistry complicates prostate cancer management. Can J Urol 2002; 9: 1496–1497.

    PubMed  Google Scholar 

  9. Kummar S, Shafi NQ . False elevations in prostate-specific antigen levels affecting patient management. Clin Adv Hematol Oncol 2004; 2: 599–601; discussion 2.

    PubMed  Google Scholar 

  10. Warren DJ, Bjerner J, Paus E, Bormer OP, Nustad K . Use of an in vivo biotinylated single-chain antibody as capture reagent in an immunometric assay to decrease the incidence of interference from heterophilic antibodies. Clin Chem 2005; 51: 830–838.

    Article  CAS  Google Scholar 

  11. Boscato LM, Stuart MC . Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988; 34: 27–33.

    Article  CAS  Google Scholar 

  12. Cantor D . Reason for limitations of heterophilic blocking tube use on certain beckman coulter access assays. Clin Chem 2005; 51: 1311.

    Article  CAS  Google Scholar 

  13. Bertholf RL, Johannsen L, Guy B . False elevation of serum CA-125 level caused by human anti-mouse antibodies. Ann Clin Lab Sci 2002; 32: 414–418.

    PubMed  Google Scholar 

  14. Sapin R, Simon C . False hyperprolactinemia corrected by the use of heterophilic antibody-blocking agent. Clin Chem 2001; 47: 2184–2185.

    Article  CAS  Google Scholar 

  15. Pathologists CoA. K-18 General Ligand Assay Participant Summary. General Ligand Assay Proficiency Testing 2011.

  16. Kaplan LA, Pesce AJ . Clinical Chemistry: Theory, Analysis, and Correlation. 3rd ed. Mosby: St Louis, 1996.

    Google Scholar 

  17. Boscato LM, Stuart MC . Heterophilic antibodies: a problem for all immunoassays. Clin Chem 1988; 34: 27–33.

    Article  CAS  Google Scholar 

  18. Preissner CM, Dodge LA, O’Kane DJ, Singh RJ, Grebe SK . Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. Clin Chem 2005; 51: 208–210.

    Article  CAS  Google Scholar 

  19. Ismail Y, Ismail AA . Erroneous laboratory results: what clinicians need to know. Clin Med 2007; 7: 357–361.

    Article  Google Scholar 

  20. Bjerner J, Nustad K, Norum LF, Olsen KH, Bormer OP . Immunometric assay interference: incidence and prevention. Clin Chem 2002; 48: 613–621.

    Article  CAS  Google Scholar 

  21. Boerman OC, Segers MF, Poels LG, Kenemans P, Thomas CM . Heterophilic antibodies in human sera causing falsely increased results in the CA 125 immunofluorometric assay. Clin Chem 1990; 36: 888–891.

    Article  CAS  Google Scholar 

  22. Levin O, Morris LF, Wah DT, Butch AW, Yeh MW . Falsely elevated plasma parathyroid hormone level mimicking tertiary hyperparathyroidism. Endocr Pract 2011; 17: e8–11.

    Article  Google Scholar 

  23. Ross HA, Menheere PP, Thomas CM, Mudde AH, Kouwenberg M, Wolffenbuttel BH . Interference from heterophilic antibodies in seven current TSH assays. Ann Clin Biochem 2008; 45 (Pt 6): 616.

    Article  CAS  Google Scholar 

  24. Spencer DV, Nolte FS, Zhu Y . Heterophilic antibody interference causing false-positive rapid human immunodeficiency virus antibody testing. Clin Chim Acta 2009; 399: 121–122.

    Article  CAS  Google Scholar 

  25. Butler SA, Cole LA . Use of heterophilic antibody blocking agent (HBT) in reducing false-positive hCG results. Clin Chem 2001; 47: 1332–1333.

    Article  CAS  Google Scholar 

  26. Zhu Y, Jenkins MM, Brass DA, Ravago PG, Horne BD, Dean SB et al. Heterophilic antibody interference in an ultra-sensitive 3-site sandwich troponin I immunoassay. Clin Chim Acta 2008; 395: 181–182.

    Article  CAS  Google Scholar 

  27. Hunter WM, Budd PS . Circulating antibodies to ovine and bovine immunoglobulin in healthy subjects: a hazard for immunoassays. Lancet 1980; 2: 1136.

    Article  CAS  Google Scholar 

  28. Leibowitz SB, Oh WK . Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. J Urol 2003; 170 (4 Pt 1): 1305.

    Article  Google Scholar 

  29. Bjerner J, Bormer OP, Nustad K . The war on heterophilic antibody interference. Clin Chem 2005; 51: 9–11.

    Article  CAS  Google Scholar 

  30. Soletormos G, Semjonow A, Sibley PE, Lamerz R, Petersen PH, Albrecht W et al. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice. Clin Chem 2005; 51: 1342–1351.

    Article  Google Scholar 

  31. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D’Amico AV, Dmochowski RR et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007; 177: 540–545.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. C B Anderson and A L Pyle: These authors equally contributed to this work.

Authors and Affiliations

  1. Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA

    C B Anderson, M S Cookson, J A Smith Jr & D A Barocas

  2. Department of Pathology, Vanderbilt University Medical Center, Nashville, TN, USA

    A L Pyle & A Woodworth

  3. Vanderbilt Center for Surgical Quality and Outcomes Research, Nashville, TN, USA

    D A Barocas

Authors
  1. C B Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A L Pyle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Woodworth
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M S Cookson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J A Smith Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D A Barocas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C B Anderson.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Anderson, C., Pyle, A., Woodworth, A. et al. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies. Prostate Cancer Prostatic Dis 15, 182–188 (2012). https://doi.org/10.1038/pcan.2011.58

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2011.58

Keywords

Search

Advanced search

Quick links